"The aging baby boomers and omnipresent desire to fight and better treat all forms of cancer are driving research and patent filings that may be of great interest to investors on both an investment and personal health level," stated SmallCap Sentinel analyst D.R. Clark. "The MultiCell Technologies, Inc. (OTCBB:MCET) filing of a patent that provides a potential method for treating a range of malignant tumors using the company's technologies to alter the immune system is a recent example of this."
"Historically, broadening markets drive ingenuity," stated Clark. "And the results can be fantastic and impacting."
An informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" has been made available via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The report will address Merck Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), Amgen (Nasdaq:AMGN), and MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report isn't investment advice. MP has been paid $1,500 for preparation and distribution of this report and other advertising services by MultiCell Technologies, Inc. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.
CONTACT: Market Pathways/StockUpTicks
Kurt Divich, Editor
(702) 396-1000
All of the above text is a press release provided by the quoted organization. TheMatureMarket.com accepts no responsibility for their accuracy.
Home page
